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Prognostic Importance of the Mitotic Marker
Phosphohistone H3 in Cutaneous Nodular Melanoma
Rita G. Ladstein1, Ingeborg M. Bachmann1,2, Oddbjørn Straume1 and Lars A. Akslen1,3
Mitotic count is a known prognostic predictor in cutaneous melanoma, and is included in the current American
Joint Committee on Cancer tumor-node-metastasis (TNM) staging system. The mitotic marker phosphohistone
H3 (PHH3) is considered to facilitate counting of mitosis, and the purpose of this study was to evaluate the
prognostic significance and strength of PHH3 in comparison with standard mitotic counting in cutaneous
malignant melanoma. A total of 457 consecutive cases of nodular cutaneous melanoma were initially included in
this series. The mitotic count was assessed on hematoxylin and eosin sections, and PHH3 was then examined by
immunohistochemistry on standard sections of paraffin-embedded tumor tissue. Both the mitotic count and
the number of PHH3-stained mitotic figures were recorded in a minimum area of 1mm2. Increased mitotic
count and PHH3 value were both associated with unfavorable features like tumor thickness and presence of
ulceration. Univariate survival analysis showed a highly significant prognostic impact of mitotic count and
PHH3, whereas multivariate analysis indicated PHH3 to be a stronger prognostic indicator than mitotic count.
Assessment of mitotic activity by PHH3 immunostaining might have important practical advantages, and should
be further studied to consider a place in routine examination of all cutaneous melanomas.
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INTRODUCTION
Tumor cell proliferation is a major determinant of cancer
progression (Hanahan and Weinberg, 2011). In cutaneous
melanoma, there is a need for improved diagnostic and
prognostic markers to stratify treatment and follow-up. In
2010, mitotic count was included in the substaging of pT1
melanoma, according to the AJCC (American Joint Commit-
tee on Cancer) classification (Balch et al., 2009b). In the
multivariate analysis, which formed the basis of these revised
guidelines, mitotic count was the second strongest prognostic
factor after tumor thickness in cases with localized melanoma
(Thompson et al., 2011). Ulceration of the primary tumor
followed as the third most powerful factor. The strongest
prognostic impact of mitotic count was seen in the group of
pT1 tumors, although it was also a significant factor for
thicker lesions. In the present seventh edition of the AJCC
tumor-node-metastasis (TNM) staging system (Balch et al.,
2009a), it is recommended that mitoses should be assessed in
all primary melanomas. Although inter-observer reproduci-
bility is reported to be quite good when using a standardized
approach (Scolyer et al., 2003), mitotic counting might be
very difficult and time consuming (Attis and Vollmer, 2007).
The reproducibility is probably less in routine practice when
compared with careful scientific studies. Therefore, pre-
viously unreported and efficient proliferation markers have
been searched for.
The mitosis marker phosphohistone H3 (PHH3) has been
known since 1997 (Hendzel et al., 1997). Histone H3 (Ser 10)
is phosphorylated in association with mitotic chromatin
condensation in late G2 and M phase of the cell cycle
(Hendzel et al., 1997; Juan et al., 1998), but not during
apoptosis (Hendzel et al., 1998). Immunohistochemical
staining of PHH3 is reported to facilitate mitotic counting
and predict prognosis in different tumors such as breast
cancer (Skaland et al., 2007). Studies in melanocytic lesions
are very limited, but have suggested PHH3 as a useful
supplement in differentiating malignant melanoma from
benign nevi and to simplify the assessment of mitotic activity
in established melanomas (Tapia et al., 2006; Nasr and
El-Zammar, 2008; Casper et al., 2010; Glatz et al., 2010).
Prognostic impact of PHH3 was recently reported for uveal
melanomas (Angi et al., 2011), but has not been shown for
cutaneous melanoma.
In our recent study of cutaneous melanoma of the nodular
type, mitotic count as well as Ki-67 expression were both
found to be prognostic factors, whereas PHH3 did not show
a prognostic impact when assessed on tissue microarrays
(Ladstein et al., 2010). On this background, PHH3 in
cutaneous melanoma was suggested to be studied in
more detail, using an approach close to a possible clinical
setting. Here, we show that PHH3 expression in cutaneous
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melanoma is a better prognostic factor than standard mitotic
count, and it also has obvious practical advantages.
RESULTS
Mitotic count
The median mitotic count was 4.7 mitotic figures per mm2,
with a range from 0.0 to 87.2 mitotic figures per mm2. There
were highly significant associations between increasing
mitotic count and tumor thickness, presence of ulceration,
and advanced Clark’s level of invasion (all Po0.001;
Kruskal–Wallis or Mann–Whitney test; Table 1).
PHH3
The number of PHH3-positive mitotic figures ranged from 0.0
to 148.1 per mm2, the median value being 28.7 per mm2.
Increasing number of PHH3-positive mitotic figures was
strongly correlated to increased tumor thickness and presence
of tumor ulceration (both Po0.001; Kruskal–Wallis or
Mann–Whitney test), but not with Clark’s level of invasion
(Table 1). The Spearman’s correlation coefficient for PHH3
and mitotic count was 0.62 (Po0.001), and the relationship
is illustrated in Figure 1.
In 26 of the 345 cases (7.5%), some of the mitotic figures
were PHH3 negative, and the mean proportion of negative
mitoses in these cases was 19.3% (range 2–71%). There were
no cases with negative mitotic figures only. In 13 cases,
o10% of the mitoses were negative, and in only 3 cases the
proportion of negative mitoses was X50% of all the mitotic
figures recorded. There was no significant association
between the frequency of negative mitoses and fixation
times; median fixation time was 3.5 days in the cases with
negative mitoses compared with 4.0 day among the others.
In the subset of 54 cases where different mitotic phases
were assessed, the median frequencies of prophases,
metaphases, anaphases, and telophases were 49.1% (range
22–100%), 44.4% (range 0–66%), 6.3% (range 0–22%) and
0% (range 0–20%), respectively.
Survival analyses
Univariate survival analysis showed significant prognostic
impact of mitotic count and PHH3 count (both Po0.001;
Figure 2; Table 2), using cutoff levels at the lower quartiles. In
the cases with high mitotic count (X1.9 mitotic figures per
mm2), 5-year survival was 63% and the 10-year survival was
50%. In comparison, the 5- and 10-year survival was 84%
and 80%, respectively, in the group of cases with low mitotic
count. For cases with high PHH3 (X14.1 positive mitotic
figures per mm2), the estimated 5-year survival was 60% and
the 10-year survival was 47%. In contrast, 5-year survival was
86% and 10-year survival was 78% among the rest.
There was also a significant prognostic value of mitotic
count and PHH3 if cut-points were set at the median value or
at the upper quartile. Further, for the mitotic count, results
were not changed if the cutoff level was set at 2 mitotic
figures per mm2, as a more practical value. Similarly, results
for PHH3 analyses were not changed if the cut-point was
15 positive tumor cell nuclei per mm2. Receiver operated
characteristic curves did not indicate other cutoff levels for
mitotic count or PHH3.
In multivariate analysis (proportional hazards method),
initially the histopathological variables incorporated in the
current pT system were evaluated; tumor thickness and
ulceration were included together with mitotic count. All
variables were significant in the final model. Tumor thickness
44.0mm predicted poor prognosis compared with tumors
p2.0mm (hazard ratio (HR)¼ 2.7; P¼0.001); presence of
ulceration (HR¼1.7; P¼0.003) and high mitotic count
(HR¼ 1.9; P¼ 0.019) also indicated unfavorable prognosis.
Thereafter, the same variables were included together with
PHH3 in a new model (Table 3A). Tumor thickness and
PHH3 were significant in the final model, whereas ulcerationTable 1. Mitotic count and PHH3 count in association
with histopathological variables
Mitotic count (no. per mm2) PHH3 count (no. per mm2)
Variables N Median P-value1 N Median P-value1
Tumor thickness (mm) o0.001 o0.001
p2.0 109 1.7 78 13.5
2.1–4.0 162 3.8 124 27.5
44.0 183 9.4 143 39.8
Tumor ulceration o0.001 o0.001
Absent 231 2.8 163 17.6
Present 214 8.5 176 39.8
Clark’s level of invasion o0.001 0.078
II–IV 378 3.8 284 26.9
V 75 8.5 60 33.8
Abbreviation: PHH3, phosphohistone H3.
1Mann–Whitney or Kruskal–Wallis test.
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Figure 1. Scatter plot with regression line illustrating the relationships
between phosphohistone H3 (PHH3) count (positive tumor cells per mm2)
and mitotic count (mitoses per mm2).
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and mitotic count showed no independent significance. Next,
we included Clark’s level of invasion, tumor location and
sex, factors with significant prognostic impact in univariate
analyses. Tumor thickness, ulceration, PHH3, and Clark’s
level of invasion and sex persisted in this final model (Table
3B). Further, multivariate analysis on the subset of cases
(n¼89) with data on Ki-67 expression in addition to tumor
thickness, tumor ulceration, mitotic count, and PHH3 was
done. Number of events in this model was 40 (deaths from
melanoma). This left only Ki-67 expression (HR¼2.9;
P¼0.024) and PHH3 (HR¼ 2.4; P¼0.012) as significant
factors in the final model (Table 3C).
If the number of PHH3-negative mitotic figures was added
to the PHH3-positive stained mitotic figures, the univariate
survival analysis did not change, nor were the multivariate
models influenced.
To further compare the prognostic impact of mitotic count
and PHH3, four groups were made: cases with high mitotic
count and high PHH3, cases with low mitotic count and low
PHH3, cases with high mitotic count and low PHH3, and
cases with low mitotic count and high PHH3 (overall
Po0.001). In univariate analysis, the survival curves of the
two groups with discordant values were located in the
middle, between the two others, suggesting that these two
markers might have an additive influence on patient survival.
DISCUSSION
In the present study of relatively thick cutaneous melanomas
of the nodular type, increased mitotic count and PHH3 value
were significant prognostic factors and both associated with
known unfavorable histopathological features like tumor
thickness and presence of ulceration. To our knowledge,
prognostic impact of PHH3 count compared with mitotic
frequency in cutaneous melanomas is previously unreported,
and this melanoma marker might be of possible practical
value.
Tumor cell proliferation is a prognostic factor in malignant
melanoma, and mitotic count is recommended to be assessed
in all primary melanomas according to current guidelines
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Figure 2. Survival curves according to the Kaplan–Meier method with cutoff
points at the lower quartile for mitotic count (o1.9mitoses per mm2) and
phosphohistone H3 (PHH3; o14.1 positive mitotic figures per mm2).
Table 2. Univariate survival analysis according to
histopathological variables and proliferation markers
Estimated survival rates (%)
Variables N 5 years 10 years P-value1
Tumor thickness (mm) o0.001
p2.0 109 86 81
2.1–4.0 164 72 57
44.0 184 54 42
Tumor ulceration o0.001
Absent 233 80 71
Present 215 55 43
Clark’s level of invasion o0.001
II–IV 381 72 62
V 75 45 28
Mitotic count (no. per mm2) o0.001
o1.92 112 84 80
X1.9 342 63 50
PHH3 count (no. per mm2) o0.001
o14.12 86 85 78
X14.1 259 60 47
Ki-67 (% pos.)3 o0.001
p16.02 49 86 84
416.0 138 58 47
Abbreviations: PHH3, phosphohistone H3; pos., positive.
1Log-rank test.
2Cutoff point lower quartile.
3Examined in cases from 1981 to 1997.
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(Balch et al., 2009a). The assessment of mitosis should be
done in so-called ‘‘hot spots’’, the most mitotically active
tumor areas (Balch et al., 2009a). Counting mitotic figures is
an obvious method to estimate proliferative activity, but it
might be difficult and time consuming (Attis and Vollmer,
2007). Mitotic figures can sometimes be overlooked and from
time to time be difficult to distinguish from apoptotic cells.
On this background, markers that provide an enhancement of
mitotic figures are of significant interest.
Anti-PHH3 highlights mitotic figures and is reported to
facilitate mitotic counting in different tissues including
melanocytic tumors (Tapia et al., 2006; Glatz et al., 2010),
and this was also the experience in our present study.
Apoptotic cells and pyknotic nuclei remained unstained.
Accordingly, tumor areas with high mitotic activity (‘‘hot
spots’’) were easier and quicker to recognize, and counting of
mitotic figures was simpler and faster. The sensitivity for
recording mitotic tumor cell nuclei is clearly increased by
PHH3 staining compared with mitotic counts on standard
hematoxylin and eosin (H&E) sections because of the
conditions already mentioned. Another factor is that pro-
phases are detected by PHH3 staining, a mitotic phase that is
usually not noticed on H&E sections. In the subset of cases
where different mitotic phases were recorded, prophases and
metaphases dominated, and the number of anaphases and
telophases were few. In the present study, the median value
of all PHH3-stained mitotic figures was about 6-fold higher
than the mitotic count from H&E sections. One study has
described even stronger PHH3 immunohistological staining
of prophases and metaphases compared with later mitotic
phases (Tapia et al., 2006). There was no apparent explana-
tion to why some mitotic figures did not show PHH3 staining,
such as duration of fixation.
In our previous study (Ladstein et al., 2010), there was no
significant prognostic value of PHH3. There are several
possible explanations for this discrepancy. The previous study
was performed on tissue microarray sections, which are less
suitable for recording of unevenly distributed markers in the
tumor tissue, as mitotic activity might be. In contrast,
standard sections were used in the present study. Further,
the staining protocol was adjusted to improve sensitivity, and
the patient series was also expanded.
The prognostic impact of PHH3 turned out to be better
than that for mitotic count by multivariate survival analysis,
where mitotic count had no independent prognostic value.
Recording PHH3-stained mitotic figures was easier and less
time consuming with a high degree of inter-observer
reproducibility. Other authors have claimed PHH3 to have
better reproducibility than ordinary mitotic count, being less
dependent on the observer’s experience (Angi et al., 2011).
In the present study, the reproducibility of recording mitosis
by PHH3 staining and by counting mitotic figures on standard
H&E sections were at equivalent levels, but this could
probably be in favor of PHH3 in the routine setting. The
possible benefits of enhancing mitotic figures by staining of
PHH3 in cutaneous melanomas should be further examined.
In the present study, PHH3 was determined in a series of
cutaneous melanoma of the nodular type, accordingly rather
Table 3. Multivariate survival analyses
(Cox proportional hazards method)
Variables N HR1 95% CI P-value2
(A) Final model after initial inclusion (step 1) of tumor thickness, tumor
ulceration, mitotic count,3 and PHH3 count (n=338)
Tumor thickness (mm) 0.001
p2.0 78 1
2.1–4.0 119 3.2 1.32–7.88 0.010
44.0 141 4.4 1.80–10.77 0.001
Tumor ulceration 0.075
Absent 162 1
Present 176 1.5 0.95–2.37
PHH3 count (no. per mm2) 0.027
o14.13 85 1
X14.1 253 1.9 1.04–3.36
(B) Final model after initial inclusion (step 1) of tumor thickness, tumor
ulceration, mitotic count3, PHH3 count, Clark’s level, location,4 and sex
(n=333)
Tumor thickness (mm) 0.041
p2.0 77 1
2.1–4.0 118 2.8 1.13–6.77 0.026
44.0 138 2.7 1.08–6.94 0.034
Tumor ulceration 0.032
Absent 161 1
Present 172 1.6 1.03–2.58
PHH3 count (no. per mm2) 0.023
o14.13 84 1
X14.1 249 1.9 1.06–3.38
Clark’s level of invasion 0.002
II–IV 275 1
V 58 2.4 1.41–3.96
Sex o0.001
Female 151 1
Male 182 2.1 1.39–3.27
(C) Final model after initial inclusion (step 1) of tumor thickness, tumor
ulceration, mitotic count3, PHH3 count, and Ki-67 (n=89)
PHH3 (no. per mm2) 0.012
o14.13 35 1
X14.1 54 2.4 1.16–4.97
Ki-67 (% pos.) 0.024
p16.03 22 1
416.0 67 2.9 1.01–8.17
Abbreviations: CI, confidence interval; HR, hazard ratio; PHH3,
phosphohistone H3; pos., positive.
1Hazard ratio.
2Likelihood ratio or Wald test.
3Cutoff point at lower quartile.
4Trunk compared with other sites.
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thick tumors, whereas the most common histological subtype
is the superficial spreading melanoma. To the best of our
knowledge, an independent prognostic value of histological
subtype (nodular compared with superficial spreading) is not
shown, when tumor thickness is included in the analyses
(Scolyer et al., 2009). Consequently, one can speculate that
the results in the present study would be similar for superficial
spreading cutaneous melanomas with comparable thickness.
Thus, our findings need confirmation in larger series across
different growth patterns of invasive melanoma, and espe-
cially the prognostic impact of PHH3 in thinner melanomas
of the superficial spreading type has to be determined.
Conclusions
Mitotic count and PHH3 value were significant prognostic
indicators in this series of thick cutaneous melanomas, with
PHH3 having an independent impact by multivariate analysis
in contrast to mitotic count. The assessment of mitotic activity
by PHH3 immunostaining of mitotic figures might have
important practical advantages, and our results should be
validated in larger series to consider a place in routine
examination of cutaneous melanomas, as PHH3 counts
represents a different measure than standard mitotic fre-
quency.
MATERIALS AND METHODS
Patients
This patient series consists of consecutive cases of nodular cutaneous
melanoma diagnosed at the Department of Pathology, Haukeland
University Hospital (Bergen, Norway) during 1981–2008. All cases
diagnosed as melanoma of the nodular type, or not otherwise
specified, were reviewed by microscopy, and 457 cases were finally
included. The presence of a vertical growth phase and the lack of
a radial growth phase, i.e. adjacent in situ or microinvasive
components, were used as inclusion criteria. Cases with minor
secondary involvement of the adjacent epidermis up to three
epidermal ridges were included. There was no known history of
familial occurrence. During this period, the sentinel node procedure
was not performed. The first part of this series (1981–1997) is
described in detail elsewhere (Straume et al., 2000), and before the
present study, the series was expanded with cases from 1998 to
2008. The median age was 68 years and the median tumor thickness
was 3.6mm (range 0.7–44.0mm).
Complete information on patient survival with time and cause of
death was available in all 457 cases. Last date of follow-up was 31
December 2008, and median follow-up time for survivors was 61.5
months (range from 0 to 330 months). During the follow-up period,
147 patients (32%) died of malignant melanoma and 100 (22%) died
of other causes.
The Norwegian Data Inspectorate and the Regional Committee
for Ethics in Research (Health Region III; 178.05) have approved this
project. The study was performed in accordance with the Declara-
tion of Helsinki Principles.
Previously reported information on clinicopathological charac-
teristics (Straume et al., 2000), the proliferation marker Ki-67
(Straume et al., 2000), and mitotic count (Ladstein et al., 2010) for
a subset of the series was included for comparison. Ki-67 was
examined in the first part of this series (1982–1997).
Clinicopathological variables
The following variables were recorded: date of histological
diagnosis, sex, and age at diagnosis and anatomical site of the
primary tumor. The H&E-stained slides of the cases were re-
examined, and the following histological features were included in
this study: tumor thickness according to Breslow (1970), level of
invasion according to Clark et al. (1969), and microscopic tumor
ulceration (Straume and Akslen, 2001).
Mitotic count. The mitotic count was recorded on H&E-stained
sections, in the lower half of the tumors, using a light microscope
( 400). Mitotic figures were counted in the most active area (‘‘hot
spots’’), in line with the AJCC recommendation (Balch et al., 2009a).
Consecutive high power fields were examined to assess an area of at
least 1mm2, and the number of mitosis per mm2 was calculated
(RGL, LAA). There was very good agreement between the two
observers (Spearman’s correlation coefficient 0.82, Po0.001) in a
random sample of 50 cases.
Immunohistochemistry
PHH3. The immunohistochemical staining was performed on
standard sections (5 mm) of paraffin-embedded archival tissue.
Sufficient tumor tissue was available in 345 cases, i.e. in 253 of
255 of the cases included before the present study, and in 92 of the
202 cases included earlier (1981–1997). To optimize sensitivity,
some adjustments in the staining protocol compared with a previous
study were done (Ladstein et al., 2010). The slides were dewaxed
with xylene/ethanol before heat-induced antigen retrieval in a
pressure cooker for 10 minutes at 1251C in Tris-EDTA buffer
(pH¼ 9). After cooling, the slides were incubated for 1 hour at room
temperature with a polyclonal rabbit PHH3 antibody (Ser 10),
catalog # 06-570 (Millipore, Billerica, MA), diluted 1:1,500.
Endogenous peroxidase activity was blocked. Detection was done
using the Advance HRP method (Dako, Copenhagen, Denmark),
with 3-amino-9-ethylcarbazole peroxidase as substrate before brief
counterstaining with Dako REAL hematoxylin. Except the hemato-
xylin counterstaining, all the staining procedures were performed
using the DAKO Autostainer. Sections from selected cases were used
as positive and negative controls in every staining operation.
Negative controls were obtained by omitting the primary antibody.
Evaluation of staining
PHH3 was recorded by counting of positive tumor cells in prophase,
metaphase, anaphase, or telophase (Figure 3). Stained tumor cell
nuclei with chromatin condensation and lack of an intact nuclear
membrane were counted. Some interphase nuclei showed weak
granular staining, but these were not counted. The counting was
done in the lower half of the tumors, in the hot spot areas with
highest mitotic frequency. Adjacent high power fields were counted
to assess an area of at least 1mm2 (magnification  400, field size
0.18mm2). In cases with less tumor tissue, as many high power fields
as possible were counted. The number of immunolabeled mitosis
per mm2 was calculated. A subset (n¼ 25) was scored blindly by two
observers (RGL, IMB) showing very good agreement (Spearman’s
correlation coefficient 0.88, Po0.001). Evaluation of the cases was
done blinded for patient characteristics and outcome.
PHH3-negative tumor cells in mitosis were recorded simulta-
neously. Further, in a subset (n¼ 54), the different phases of mitosis
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were separately recorded as prophases, metaphases, anaphases, or
telophases.
Statistics
Analyses were performed using the SPSS statistical package, version
15.0 (SPSS, Chicago, IL). Continuous variables not following the
normal distribution were compared between two or more groups
using the Mann–Whitney U or Kruskal–Wallis H tests. Nonpara-
metric correlations were tested by the Spearman’s rank coefficient.
In subsequent statistical analyses, the cutoff point for categorization
was based on the lower quartile values for the mitotic count and
PHH3 after considering the frequency distribution curves and size
of subgroups, as well as number of events. Receiver operated
characteristic analyses were also performed.
Univariate analyses of time to death due to malignant melanoma
were performed using the product-limit procedure (Kaplan–Meier
method), and differences between categories were estimated by the
log-rank test, with date of histological diagnosis as starting point.
Patients who died of other causes than melanoma were censored at
the date of death. The influence of covariates on patient survival and
recurrence-free survival was analyzed by the proportional hazards
method, and tested by the backward stepwise likelihood ratio test.
The variables were tested by log–log plot to determine their ability to
be incorporated in multivariate models. All results were considered
significant if Pp0.05.
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